课题基金 / 基金详情

Anti-parathyroid hormone-related protein (PTHrP) monoclonal antibodies against metastatic cancer

Anti-parathyroid hormone-related protein (PTHrP) monoclonal antibodies against metastatic cancer
抗转移性癌症的抗甲状旁腺激素相关蛋白 (PTHrP) 单克隆抗体
批准号:
470394
负责人:
Kremer Richard B
金额:
$48.49万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2022
资助国家:
加拿大
项目状态:
未结题
起止时间:
2022-09-01 至 2025-09-01

项目摘要

项目成果

Kremer Richard B的其他基金

相似基金

相关文献

中文摘要
翻译
在发达国家,癌症是导致死亡的主要原因;加拿大癌症协会估计,到2022年,加拿大将有233,900例新病例和85100例癌症死亡。可怕的是,四分之一的加拿大人将死于这种疾病。大多数canc
英文摘要
Cancer is the leading cause of death in the developed world; the Canadian Cancer Society estimates that there will be 233,900 new cases and 85,100 deaths from cancer in Canada in 2022. Frighteningly, 1 out of 4 Canadians will die of the disease. Most canc
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Co-targeting parathyroid hormone-related protein (PTHrP) and osteoclast activation to counter breast cancer metastasis to bone.
Effect of 1,25 dihydroxyvitamin D on control of cell growth and differentiation
Co-targeting parathyroid-hormone related protein (PTHrP) signaling and osteoclast activation to counter breast cancer metastasis to bone
  • 批准号:
    321112
  • 项目类别:
    Operating Grants
  • 资助金额:
    $53.91万
  • 财政年份:
    2015
  • 负责人:
    Kremer Richard B
  • 依托单位:
Effect of 1,25 dihydroxyvitamin D on control of cell growth and differentiation
  • 批准号:
    280255
  • 项目类别:
    Operating Grants
  • 资助金额:
    $50.07万
  • 财政年份:
    2013
  • 负责人:
    Kremer Richard B
  • 依托单位:
海外基金